Department of Tuberculosis Control and Prevention, Guangzhou Chest Hospital, Guangzhou, China.
Academy of Public Health, Guangzhou Medical University, Guangzhou, China.
Front Public Health. 2024 Mar 27;12:1372389. doi: 10.3389/fpubh.2024.1372389. eCollection 2024.
Mental health disorders in patients with multi-drug or rifampicin-resistant tuberculosis (MDR/RR-TB) receive consistent attention. Anxiety and depression can manifest and may impact disease progression in patients with MDR/RR-TB. Given the heightened stressors resulting from the COVID-19 pandemic, this scenario is even more concerning.
To evaluate the prevalence of and risk factors associated with anxiety and depression among patients with MDR/RR-TB in southern China.
A facility-based cross-sectional study was undertaken at Guangzhou Chest Hospital in southern China, encompassing a cohort of 219 patients undergoing outpatient and inpatient treatment for MDR/RR-TB. Anxiety and depressive symptoms were assessed using the 7-Item Generalized Anxiety Disorder (GAD-7) scale and Patient Health Questionnaire-9 (PHQ-9). The ramifications of anxiety and depression were examined using univariate and multivariate logistic regression analyses, with odds ratios (ORs) and age- and sex-adjusted ORs (AORs) employed to quantify their influence. All data underwent statistical analysis using SPSS 25.0, with statistical significance established at < 0.05.
Two hundred and nineteen individuals with MDR/RR-TB were included in the study. The prevalence of anxiety and depression was 57.53% ( = 126) and 65.75% ( = 144), respectively, with 33.3% ( = 73) of the participants experiencing both conditions simultaneously. Multivariate logistic regression analysis revealed that an age of 20-40 years [anxiety AOR = 3.021, 95% confidence interval (CI): 1.240-7.360; depression AOR = 3.538, 95% CI: 1.219-10.268], disease stigma (anxiety AOR = 10.613, 95% CI: 2.966-37.975; depression AOR = 4.514, 95% CI: 2.051-10.108) and poor physical health (anxiety AOR = 7.636, 95% CI: 2.938-19.844; depression AOR = 6.190, 95% CI: 2.468-15.529) were significant risk factors for moderate levels of anxiety and depression.
We found that individuals with MDR/RR-TB had an elevated risk of anxiety and depression. To decrease the likelihood of unfavorable treatment outcomes, it is imperative to carefully monitor the psychological wellbeing of patients with MDR/RR-TB and promptly address any detrimental psychiatric conditions.
患有耐多药/利福平耐药结核病（MDR/RR-TB）的患者的精神健康障碍一直受到关注。焦虑和抑郁可能会在 MDR/RR-TB 患者中表现出来，并可能影响疾病的进展。鉴于 COVID-19 大流行带来的压力，这种情况更加令人担忧。
评估中国南方 MDR/RR-TB 患者中焦虑和抑郁的患病率及其相关风险因素。
在中国南方的广州胸科医院进行了一项基于机构的横断面研究，纳入了 219 名正在接受门诊和住院治疗的 MDR/RR-TB 患者。使用 7 项广泛性焦虑症（GAD-7）量表和患者健康问卷-9（PHQ-9）评估焦虑和抑郁症状。使用单变量和多变量逻辑回归分析评估焦虑和抑郁的后果，使用优势比（OR）和年龄和性别调整的 OR（AOR）来量化其影响。所有数据均使用 SPSS 25.0 进行统计分析，显著性水平设为 < 0.05。
研究纳入了 219 名 MDR/RR-TB 患者。焦虑和抑郁的患病率分别为 57.53%（n=126）和 65.75%（n=144），其中 33.3%（n=73）的患者同时存在两种情况。多变量逻辑回归分析显示，年龄在 20-40 岁（焦虑 AOR=3.021，95%置信区间（CI）：1.240-7.360；抑郁 AOR=3.538，95%CI：1.219-10.268）、疾病污名（焦虑 AOR=10.613，95%CI：2.966-37.975；抑郁 AOR=4.514，95%CI：2.051-10.108）和身体状况不佳（焦虑 AOR=7.636，95%CI：2.938-19.844；抑郁 AOR=6.190，95%CI：2.468-15.529）是中重度焦虑和抑郁的显著风险因素。
我们发现 MDR/RR-TB 患者有较高的焦虑和抑郁风险。为了降低不良治疗结局的可能性，必须仔细监测 MDR/RR-TB 患者的心理健康，并及时处理任何不利的精神疾病状况。
